Clinical trials: Psoriasis Vulgaris
Psoriasis Vulgaris
Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body.
- Trial name
- NCT00704262
- Testing
- Calcipotriol plus hydrocortisone (LEO 80190)
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 33 people
- Sponsor
- LEO Pharma
Plaque Psoriasis Vulgaris
Bioavailability of AZD0284 and IV Microtracer Study
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- NCT03029741
- Testing
- AZD0284, [14C]AZD0284
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris
This study will compare efficacy and safety of once daily treatment of calcipotriol plus betamethasone dipropionate gel (LEO 80185) with tacalcitol ointment and LEO 80185 vehicle alone in subjects with psoriasis vulgaris.
- Trial name
- NCT00670241
- Testing
- calcipotriol and betamethasone (LEO 80185 gel), LEO 80185 vehicle, Tacalcitol ointment
- Where
- Canada
- Volunteers
- 458 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 22811 in healthy male subjects as well as to determine the safety and tolerability of single oral…
- Trial name
- NCT00833872
- Testing
- LEO 22811
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis
To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.
- Trial name
- NCT02668692
- Testing
- LEO 80185 gel, Dovobet ® ointment
- Where
- Japan
- Volunteers
- 213 people
- Sponsor
- LEO Pharma
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Psoriasis Vulgaris
Blue Light for Treating Psoriasis Vulgaris
The purpose of this study is to determine the efficacy and safety of a blue light device for treating Psoriasis vulgaris. The study will compare a blue light treated plaque with an untreated control plaque.
- Trial name
- NCT02004847
- Testing
- PSO-CT02
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Philips Electronics Nederland BV